ValuEngine upgraded shares of Insys Therapeutics (NASDAQ:INSY) from a strong sell rating to a sell rating in a report issued on Wednesday, March 14th.
A number of other research firms also recently commented on INSY. Zacks Investment Research downgraded shares of Insys Therapeutics from a hold rating to a sell rating in a research report on Saturday, February 3rd. Oppenheimer reissued a hold rating on shares of Insys Therapeutics in a research report on Sunday, March 11th. Piper Jaffray downgraded shares of Insys Therapeutics from a neutral rating to an underweight rating in a research report on Friday, March 9th. Finally, Cann reissued an average rating on shares of Insys Therapeutics in a research report on Friday, March 2nd. Four analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $9.38.
INSY stock traded up $0.01 during trading on Wednesday, hitting $6.27. The company had a trading volume of 270,630 shares, compared to its average volume of 601,136. The company has a market capitalization of $461.77, a PE ratio of -12.80 and a beta of 1.13. Insys Therapeutics has a 52-week low of $4.10 and a 52-week high of $15.02.
Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.47). The company had revenue of $31.49 million during the quarter, compared to analysts’ expectations of $34.00 million. Insys Therapeutics had a negative return on equity of 24.02% and a negative net margin of 162.07%. The company’s quarterly revenue was down 42.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.03 EPS. analysts predict that Insys Therapeutics will post -0.83 earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the company. Raymond James & Associates boosted its holdings in shares of Insys Therapeutics by 93.5% in the 4th quarter. Raymond James & Associates now owns 31,008 shares of the specialty pharmaceutical company’s stock valued at $298,000 after buying an additional 14,982 shares in the last quarter. Stone Ridge Asset Management LLC bought a new stake in shares of Insys Therapeutics in the 4th quarter valued at about $137,000. Deutsche Bank AG boosted its holdings in shares of Insys Therapeutics by 116.1% in the 4th quarter. Deutsche Bank AG now owns 53,827 shares of the specialty pharmaceutical company’s stock valued at $515,000 after buying an additional 28,923 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in shares of Insys Therapeutics by 9.7% in the 4th quarter. Alliancebernstein L.P. now owns 74,620 shares of the specialty pharmaceutical company’s stock valued at $718,000 after buying an additional 6,600 shares in the last quarter. Finally, Virtu Financial LLC boosted its holdings in shares of Insys Therapeutics by 96.8% in the 4th quarter. Virtu Financial LLC now owns 20,061 shares of the specialty pharmaceutical company’s stock valued at $193,000 after buying an additional 9,866 shares in the last quarter. Institutional investors and hedge funds own 24.04% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/insys-therapeutics-insy-stock-rating-upgraded-by-valuengine.html.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.